Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
10:30am, Friday, 11'th Apr 2025
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told
This Pharma Giant Will Invest $23 Billion in the U.S. It's a Sign Trump's Tariffs Are Working.
08:28am, Friday, 11'th Apr 2025
The Company spend billions to produce 100% of its key medicines for Americans in the U.S.
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
10:06am, Thursday, 10'th Apr 2025
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pharma Stocks Rebound as Trump Announces a 90-Day Pause on Tariffs
09:55am, Thursday, 10'th Apr 2025
The news of a likely import tariff hurt the share price of pharma giants like Novo Nordisk (NVO), Eli Lilly (LLY) and AstraZeneca (AZN), but Trump's announcement of a pause on reciprocal tariffs offse
AbbVie Stock Up 9.2% After Key Signal
07:43am, Thursday, 10'th Apr 2025
ALERT COMES AT LOW POINT FOR ABBV AND SIGNALS MAJOR REVERSAL OF OVER 15 POINTS
Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkback
04:45am, Thursday, 10'th Apr 2025
European stocks soared on Thursday after U.S. President Donald Trump's jarring about-turn on most tariffs. Tensions between Washington and Beijing remain high, however, with Trump ratcheting up duties
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
06:32pm, Wednesday, 09'th Apr 2025
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
AbbVie: Thriving Beyond Humira's Patent Cliff (Upgrade)
05:29pm, Wednesday, 09'th Apr 2025
AbbVie stock outperformed S&P 500 with a +16% to 9.41% return since November 2023, despite Humira revenue declining 38% to $8.99 billion. Immunology drugs Skyrizi and Rinvoq grew over 50% year-over-ye
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
03:59pm, Wednesday, 09'th Apr 2025
The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturin
Explainer: Prescription drugs become a target in Trump's trade war
02:27pm, Wednesday, 09'th Apr 2025
U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm t
Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'
01:06pm, Wednesday, 09'th Apr 2025
Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.
Why drug stocks are no longer a safe haven from the stock market's turmoil
11:49am, Wednesday, 09'th Apr 2025
Shares of drugmakers were taking a broad beating Wednesday, after President Donald Trump indicated that pharmaceuticals will no longer be excluded from tariffs.
2 Top Dividend Stocks That Could Set You Up for Life
07:00am, Wednesday, 09'th Apr 2025
With equity markets in shambles due to President Donald Trump's trade policies, now might be as good a time as any to invest in excellent dividend stocks.
AbbVie's Rinvoq Gets EU Nod for 8th Indication Giant Cell Arteritis
10:15am, Tuesday, 08'th Apr 2025
European Commission approves ABBV's Rinvoq for its eighth indication, giant cell arteritis.
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis
02:00am, Tuesday, 08'th Apr 2025
RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval is supported by data from the pi
